What is the primary purpose of the agreement with ATI/MCDC?

The primary purpose is for Regeneron to manufacture and deliver its investigational dual antibody treatment, REGN-COV2 (or other monoclonal antibodies), to the U.S. Government, aimed at preventing or treating COVID-19.

What is the total potential value of the MCDC Agreement?

The MCDC Agreement has a potential aggregate value of up to $450.2 million, with $445.0 million tied to manufacturing milestones and $5.2 million for storage.

When will Regeneron start manufacturing and delivering the COVID-19 treatment under this agreement?

Bulk manufacturing of the drug substance is planned for the summer through fall of 2020. Fill/finish and storage activities are scheduled to begin in the third quarter of 2020.

Does the U.S. Government have any rights to terminate this agreement?

Yes, the agreement includes customary terms for U.S. Government contracts, allowing the government to terminate the agreement based on a reasonable determination that the project will not produce beneficial results commensurate with the expenditure of resources.

REGN 8-K: Material Agreements & Regulation FD

Summary

Regeneron Pharmaceuticals, Inc. (REGN) announced on July 7, 2020, that it has entered into a material definitive agreement with Advanced Technology International, Inc. (ATI) on behalf of the Medical CBRN Defense Consortium (MCDC) for the U.S. Government. This agreement, termed the MCDC Agreement, involves the manufacture and delivery of Regeneron's investigational dual antibody treatment, REGN-COV2 (consisting of REGN10987 and REGN10933), or other monoclonal antibodies, aimed at preventing or treating COVID-19. The MCDC Agreement has a potential aggregate value of up to $450.2 million. This funding is tied to manufacturing milestones and storage services, with the bulk manufacturing scheduled for the summer and fall of 2020, and fill/finish activities commencing in Q3 2020. While this agreement provides significant potential revenue, it also includes terms customary for U.S. Government contracts, such as the government's right to terminate if the project is not deemed beneficial. Regeneron expects to provide updated full-year 2020 financial guidance reflecting this agreement during its second-quarter earnings announcement.

Key Highlights

1Regeneron has signed a material agreement with the U.S. Government (via ATI/MCDC) for its investigational COVID-19 antibody treatment, REGN-COV2.
2The agreement, named the MCDC Agreement, has a potential value of up to $450.2 million.
3The funding is contingent upon manufacturing milestones for the drug product and includes payments for storage.
4Manufacturing of the drug substance is slated for summer/fall 2020, with fill/finish activities starting in Q3 2020.
5The agreement allows for the potential use of REGN-COV2 or other monoclonal antibodies (as monotherapies or cocktails) for COVID-19 prevention or treatment.
6Customary U.S. Government contract terms are included, such as termination rights for the government if the project is not producing beneficial results.
7Regeneron will update its full-year 2020 financial guidance in its Q2 2020 earnings release to reflect the impact of this agreement.

REGENERON PHARMACEUTICALS, INC. 8-K Report, Material Agreement (Jul 7, 2020)

Summary

Key Highlights

Frequently Asked Questions